{
  "date": "2026-02-18",
  "items": [
    {
      "id": "1",
      "headline": "Can Treg cell therapy really target autoimmunity?",
      "preview": "Treg cell therapy is emerging as a promising approach for treating autoimmune diseases.",
      "article": "Regulatory T cells (Tregs) are being engineered as therapies to regulate an overactive immune system. Treg cell therapies are being explored for conditions like type 1 diabetes and multiple sclerosis, potentially reshaping precision medicine.\nWhy this matters: The recent Nobel Prize awarded for Treg discoveries highlights their significance in immunotherapy, and companies like Sonoma Biotherapeutics are advancing Treg therapies like SBT-77-7101, which shows promise in reducing inflammation in rheumatoid arthritis.\nAs various biotechs explore Treg therapies, the goal remains to curb inflammation and treat autoimmunity effectively, paving the way for innovative treatments.",
      "sources": [
        {
          "name": "Labiotech.eu",
          "url": "https://www.labiotech.eu/in-depth/treg-cell-therapy/",
          "type": "news",
          "verified_date": "2026-02-17"
        }
      ]
    },
    {
      "id": "2",
      "headline": "Newron secured \u20ac38m to test a potential new class in schizophrenia",
      "preview": "Newron Pharmaceuticals has secured funding to advance evenamide for schizophrenia treatment.",
      "article": "Newron Pharmaceuticals has obtained up to \u20ac38 million to support Phase III trials of evenamide, a drug that could represent a novel approach to treating schizophrenia. The funding includes an upfront payment and milestone payments tied to trial success.\nWhy this matters: Evenamide aims to address treatment-resistant schizophrenia by modulating neural circuits rather than solely targeting dopamine receptors, potentially offering a new therapeutic option for patients who do not respond to existing treatments. The upcoming Phase III results are crucial for validating this approach.",
      "sources": [
        {
          "name": "European Biotechnology Magazine",
          "url": "https://european-biotechnology.com/latest-news/newron-secured-e38m-to-test-a-potential-new-class-in-schizophrenia/",
          "type": "news",
          "verified_date": "2026-02-17"
        }
      ]
    },
    {
      "id": "3",
      "headline": "Biotech Beactica and research institute LISCO secured \u20ac2.5M to advance glioblastoma therapy to the clinic",
      "preview": "Beactica and LISCO received funding to develop a glioblastoma therapy using BEA-17.",
      "article": "The European Innovation Council has funded the GLIOBREAK project, a collaboration between Beactica Therapeutics and LISCO, to advance BEA-17, a small-molecule candidate for glioblastoma treatment. The project aims to validate the drug's efficacy and prepare it for clinical trials.\nWhy this matters: Glioblastoma remains a challenging cancer with limited treatment options. The funding will support the development of precision immunotherapy, potentially improving outcomes for patients with this aggressive form of brain cancer.",
      "sources": [
        {
          "name": "European Biotechnology Magazine",
          "url": "https://european-biotechnology.com/latest-news/beactica-lisco-glioblastoma-gliobreak/",
          "type": "news",
          "verified_date": "2026-02-17"
        }
      ]
    },
    {
      "id": "4",
      "headline": "Neuromelanin MRI Beats Free Water in Early Parkinson\u2019s",
      "preview": "Neuromelanin imaging shows superior diagnostic capabilities for early Parkinson's disease.",
      "article": "A recent study has demonstrated that neuromelanin imaging significantly outperforms free water imaging in detecting early-stage Parkinson's disease. This advancement could enhance early diagnosis and treatment strategies for the condition.\nWhy this matters: Early diagnosis of Parkinson's is crucial for effective intervention. Neuromelanin imaging provides a more specific and sensitive method for identifying neurodegenerative changes, potentially leading to better patient outcomes and tailored treatment plans.",
      "sources": [
        {
          "name": "BIOENGINEER.ORG",
          "url": "https://bioengineer.org/neuromelanin-mri-beats-free-water-in-early-parkinsons/",
          "type": "news",
          "verified_date": "2026-02-18"
        }
      ]
    },
    {
      "id": "5",
      "headline": "DRfold2 is a deep learning-based tool that enables efficient and accurate RNA structure prediction",
      "preview": "DRfold2 offers a new approach to RNA structure prediction using deep learning.",
      "article": "DRfold2 is a deep learning framework designed for RNA structure prediction, achieving superior performance in predicting RNA structures from sequences. It integrates a novel RNA Composite Language Model with a denoising structure module.\nWhy this matters: Accurate RNA structure prediction is essential for understanding biological functions and developing RNA-targeted therapeutics. DRfold2's advancements could significantly enhance the field of RNA biology and drug development.",
      "sources": [
        {
          "name": "PLOS Biology",
          "url": "https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003659",
          "type": "paper",
          "verified_date": "2026-02-17"
        }
      ]
    }
  ]
}